Fracture and bone mineral density outcomes after bisphosphonate discontinuation in children with osteogenesis imperfecta treated with zoledronic acid compared to pamidronate

2015 ◽  
Author(s):  
Ryan Heksch ◽  
Sasigarn Bowden ◽  
Scott Hickey ◽  
John Mahan
Keyword(s):  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Mineral Density

The Effect of Intravenous Pamidronate on Bone Mineral Density, Bone Histomorphometry, and Parameters of Bone Turnover in Adults with Type IA Osteogenesis Imperfecta

2003 ◽  
Vol 72 (2) ◽  
pp. 103-112 ◽  
Author(s):  
J.R. Shapiro ◽  
E.F. McCarthy ◽  
K. Rossiter ◽  
K. Ernest ◽  
R. Gelman ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Turnover ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Bone Histomorphometry ◽  
Mineral Density ◽  
Type Ia ◽  
Intravenous Pamidronate

scholarly journals Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study

2017 ◽  
Vol 9 (1) ◽  
pp. 103-109 ◽  
Author(s):  
Bo-cheng Liang ◽  
Zhen-yu Shi ◽  
Bo Wang ◽  
Peng Wu ◽  
Ling-cheng Kong ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Clinical Study ◽  
Zoledronic Acid ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
East China ◽  
Newly Diagnosed ◽  
Mineral Density ◽  
Turnover Markers

scholarly journals Craniofacial Bone Mineral Density in Mice with Osteogenesis Imperfecta (OI)

2019 ◽  
Vol 33 (S1) ◽  
Author(s):  
Alexandra H McBride ◽  
Summer H Ladd ◽  
Jason M Organ ◽  
Rachel A Menegaz
Keyword(s):  
Bone Mineral Density ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Mineral Density ◽  
Craniofacial Bone

EFFECTS OF BISPHOSPHONATES ON OSTEOPOROSIS INDUCED BY DUCHENNE MUSCULAR DYSTROPHY: A PROSPECTIVE STUDY

2020 ◽  
Vol 26 (12) ◽  
pp. 1477-1485
Author(s):  
Wen-bin Zheng ◽  
Yi Dai ◽  
Jing Hu ◽  
Di-chen Zhao ◽  
Ou Wang ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Duchenne Muscular Dystrophy ◽  
Zoledronic Acid ◽  
Muscular Dystrophy ◽  
Bone Mineral ◽  
Type I Collagen ◽  
Type I ◽  
Mineral Density

Objective: Duchenne muscular dystrophy (DMD) is a severe X-linked progressive neuromuscular disease that brings a significantly increased risk of osteoporosis and bone fractures. We prospectively evaluated the effects of oral and intravenous bisphosphonates on the bones of children with DMD. Methods: This study included a total of 52 children with DMD. They were divided into zoledronic acid (ZOL), alendronate (ALN), and control groups according to bone mineral density (BMD) and history of fragility fractures. For 2 years, all patients took calcium, vitamin D, and calcitriol. Meanwhile, 17 patients received infusions of ZOL, and 18 patients received ALN. BMD, serum levels of alkaline phosphatase (ALP) and the cross-linked C-telopeptide of type I collagen (β-CTX) were evaluated. Results: After 24 months of treatment, the percentage changes in lumbar spine BMD were 23.2 ± 9.7% and 23.6 ± 8.8% in the ZOL and ALN groups (all P<.01 vs. baseline). The increases did not differ between the ZOL and ALN groups, but were significantly larger than those of the control group ( P<.01). Serum β-CTX and ALP levels, respectively, were decreased by 44.4 ± 18.0% and 31.9 ± 26.7% in the ZOL group and by 36.0 ± 20.3% and 25.8 ± 14.4% in the ALN group (all P<.01 vs. baseline). Conclusion: Zoledronic acid and alendronate had similar protective effects to increase bone mineral density and reduce bone resorption in children with DMD, which were superior to treatment of calcium, vitamin D, and calcitriol. Abbreviations: 25OHD = 25 hydroxyvitamin D; ALN = alendro-nate; ALP = alkaline phosphatase; ALT = alanine aminotransferase; BMD = bone mineral density; BP = bisphosphonate; Ca = calcium; β-CTX = cross-linked C-telopeptide of type I collagen; DMD = Duchenne muscular dystrophy; FN = femoral neck; GC = glucocorticoid; LS = lumbar spine; ZOL = zoledronic acid

scholarly journals Bone mineral density in developing children with osteogenesis imperfecta

2013 ◽  
Vol 84 (4) ◽  
pp. 431-436 ◽  
Author(s):  
Dieke H J Kok ◽  
Ralph J B Sakkers ◽  
Hans E H Pruijs ◽  
Pieter Joosse ◽  
René M Castelein
Keyword(s):  
Bone Mineral Density ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document